Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary to CRVO

NCT00088283 is registered in ClinicalTrials.gov with Eyetech Pharmaceuticals as lead sponsor.

NCT NCT00088283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00088283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary to CRVO
Lead sponsor
Eyetech Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2004
Completion date
Not reported
Enrollment
90
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

retinal vein occlusion